ABSTRACT:
The therapeutic potential of focusing on the gut microbiota to enhance medication effectiveness and customize care is examined in this review. A promising avenue for contemporary medicine is the modulation of this microbial environment, given the mounting data that links the microbiome to human health, illness development, and treatment response. The composition of the microbiota, its function in drug metabolism, and its association with a range of physiological and pathological conditions are all critically examined in this article. Probiotics, prebiotics, postbiotics, fecal microbiota transplantation, modified microorganisms, and targeted delivery methods are among the well-known and recently developed microbiota-modulating techniques that are assessed. Although these methods have the potential to provide safer and more individualized treatments, issues such as standardization, regulatory uncertainty, and inter-individual variability still persist. It is anticipated that future developments in AI and multi-omics technology will deepen our knowledge and facilitate the application of microbiome-based precision medicine in clinical settings. Major Findings: The gut microbiota has a major impact on pharmacokinetics, pharmacodynamics, toxicity, and drug efficacy. Numerous illnesses, such as neurological, immunological, metabolic, and cancer-related disorders, have been linked to dysbiosis. Drug responsiveness can be improved and microbial equilibrium restored through precise microbiome modification. Furthermore, interactions between drugs and microbiota are reciprocal; drugs can alter the composition of microbes, and microbial enzymes can modify the effects of drugs.
Cite this article:
Mehul Bhatt, Hansal Desai. Targeting Gut Microbiota in Drug Therapy: Targeting Health Through Restoration of Intestinal Viable Ecosystems (Thrive) - A New Frontier in Pharmacology. Research Journal of Pharmacognosy and Phytochemistry. 2026; 18(2):169-1. doi: 10.52711/0975-4385.2026.00024
Cite(Electronic):
Mehul Bhatt, Hansal Desai. Targeting Gut Microbiota in Drug Therapy: Targeting Health Through Restoration of Intestinal Viable Ecosystems (Thrive) - A New Frontier in Pharmacology. Research Journal of Pharmacognosy and Phytochemistry. 2026; 18(2):169-1. doi: 10.52711/0975-4385.2026.00024 Available on: https://www.rjpponline.org/AbstractView.aspx?PID=2026-18-2-9
REFERENCES:
1. Walsh J, Griffin BT, Clarke G, Hyland NP. Drug–gut microbiota interactions: implications for neuropharmacology. British Journal of Pharmacology. 2018 Dec; 175(24): 4415-29. doi:10.1111/bph.14366
2. Di Vincenzo F, Nicoletti A, Negri M, Vitale F, Zileri Dal Verme L, Gasbarrini A, et al. Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders. Antibiotics (Basel). 2023 Jun 17; 12(6): 1068. doi:10.3390/antibiotics12061068
3. Shanahan F. 99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Host–microbe interactions in the gut: target for drug therapy, opportunity for drug discovery. Clinical and Experimental Immunology. 2010 Apr; 160(1): 92-7. doi:10.1111/j.1365-2249.2010. 04135.x
4. Barone M, Rampelli S, Biagi E, Bertozzi SM, Falchi F, Cavalli A, et al. Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach. Journal of Medicinal Chemistry. 2021 Dec 9; 64(23): 17277-17286. doi: 10.1021/acs.jmedchem.1c01333.
5. Maciel-Fiuza MF, Muller GC, Campos DMS, do Socorro Silva Costa P, Peruzzo J, Bonamigo RR, et al. Role of gut microbiota in infectious and inflammatory diseases. Frontiers in Microbiology. 2023 Mar 27; 14: 1098386. doi:10.3389/fmicb.2023.1098386.
6. Di Vincenzo F, Nicoletti A, Negri M, Vitale F, Zileri Dal Verme L, Gasbarrini A, et al. Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders. Antibiotics. 2023 Jun 1; 12(6): 1068. doi:10.3390/antibiotics12061068.
7. Walsh J, Griffin BT, Clarke G, Hyland NP. Drug–gut microbiota interactions: implications for neuropharmacology. British Journal of Pharmacology. 2018 Dec 1; 175(24): 4415–29. doi:10.1111/bph.14366.
8. Ting NL-N, Lau HC-H, Yu J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut. 2022 Jul; 71(7): 1412–25. doi:10.1136/gutjnl-2021-326264.
9. Mruk-Mazurkiewicz H, Kulaszyńska M, Jakubczyk K, Janda-Milczarek K, Czarnecka W, Rębacz-Maron E, et al. Clinical Relevance of Gut Microbiota Alterations under the Influence of Selected Drugs—Updated Review. Biomedicines. 2023 Mar 1; 11(3): 952. doi:10.3390/biomedicines11030952.
10. Gebrayel P, Nicco C, Al Khodor S, Bilinski J, Caselli E, Comelli EM, et al. Microbiota medicine: towards clinical revolution. Journal of Translational Medicine. 2022 Mar 7; 20(1): 111. doi:10.1186/s12967-022-03296-9.
11. García-Cabrerizo R, Barros-Santos T, Campos D, Cryan JF. The gut microbiota alone and in combination with a social stimulus regulates cocaine reward in the mouse. Brain, Behavior, and Immunity. 2022 Oct 1; 107: 286–91. doi: 10.1016/j.bbi.2022.10.020.
12. Marashi A, Hasany SA, Moein Moghimi S, Kiani R, Mehran Asl S, Alavi Dareghlou Y, et al. Targeting gut-microbiota for gastric cancer treatment: a systematic review. Frontiers in Medicine. 2024 Aug 2; 11: 1412709. doi:10.3389/fmed.2024.1412709.
13. Mousa SNM, Sarfraz M, Mousa WK. The Interplay between Gut Microbiota and Oral Medications and Its Impact on Advancing Precision Medicine. Metabolites. 2023 May 1;13(5):674. doi:10.3390/metabo13050674.
14. Ohkusa T, Nishikawa Y, Sato N. Gastrointestinal disorders and intestinal bacteria: Advances in research and applications in therapy. Frontiers in Medicine. 2023 Feb 7; 9: 935676. doi:10.3389/fmed.2022.935676.
15. Artusa V, Calabrone L, Mortara L, Peri F, Bruno A. Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory. International Journal of Molecular Sciences. 2023 Mar 1; 24(5): 4997. doi:10.3390/ijms24054997.
16. Drapkina OM, Yafarova AA, Kaburova AN, Kiselev AR. Targeting Gut Microbiota as a Novel Strategy for Prevention and Treatment of Hypertension, Atrial Fibrillation and Heart Failure: Current Knowledge and Future Perspectives. Biomedicines. 2022 Aug 1; 10(8): 2019. doi:10.3390/biomedicines10082019.
17. Degraeve AL, Haufroid V, Loriot A, Gatto L, Franeker Jan Andries V, Vereecke L, et al. Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1. Microbiome. 2023 Jul 6; 11(1): 178. doi:10.1186/s40168-023-01578-y.
18. Flaig B, Garza R, Singh B, Hamamah S, Covasa M. Treatment of Dyslipidemia through Targeted Therapy of Gut Microbiota. Nutrients. 2023 Jan 1; 15(1): 228. doi:10.3390/nu15010228.
19. Conti G, D’Amico F, Fabbrini M, Brigidi P, Barone M, Turroni S. Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out. Genes. 2022 Dec 24; 14(1): 55. doi:10.3390/genes14010055.
20. Kouidhi S, Zidi O, Belkhiria Z, Rais H, Ben Ayed F, Mosbah A, et al. Gut microbiota, an emergent target to shape the efficiency of cancer therapy. Exploration of Targeted Anti-Tumor Therapy. 2023 Apr 26; 4: 240–65. doi:10.37349/etat.2023.00069.
21. Pant A, Maiti TK, Mahajan D, Das B. Human Gut Microbiota and Drug Metabolism. Microbial Ecology. 2022 Jul 23; 86(1): 97–111. doi:10.1007/s00248-022-02081-x.
22. Yu W, Jiang Y-F, Xu H, Zhou Y-F. The Interaction of Gut Microbiota and Heart Failure with Preserved Ejection Fraction: From Mechanism to Potential Therapies. Advances in Cardiovascular Diseases.
23. Fan H, Sheng S, Zhang F. New hope for Parkinson’s disease treatment: Targeting gut microbiota. CNS Neuroscience & Therapeutics. 2022 Jul 13; 28(11): 1675–88. doi:10.1111/cns.13931.
24. Jia L, Huang S, Sun B, Shang Y, Zhu C. Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment. Frontiers in Endocrinology. 2023 Mar 23; 14: (article number). doi:10.3389/fendo.2023.109922
25. Singh T, Kaur G, Kaur A. Dysbiosis—An Etiological Factor for Cardiovascular Diseases and the Therapeutic Benefits of Gut Microflora. 2023 Apr 4; (2023):1–8. doi:10.1155/2023/7451554.
26. Forlano R, Sivakumar M, Mullish BH, Manousou P. Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review. International Journal of Molecular Sciences. 2022 Jul 27; 23(15): 8307. doi:10.3390/ijms23158307.
27. Miftahussurur M, Freye R. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism. The FASEB Journal. 2022 May 17; 36(6): e22468. doi:10.1096/fj.202201376RR.
28. Tong S, Zhang P, Cheng Q, Chen M, Chen X, Wang Z, et al. The role of gut microbiota in gout: Is gut microbiota a potential target for gout treatment. Frontiers in Cellular and Infection Microbiology. 2022 Nov 24; 12: (article number). doi:10.3389/fcimb.2022.102433.
29. Larabi AB, Masson HLP, Bäumler AJ. Bile acids as modulators of gut microbiota composition and function. Gut Microbes. 2023; 15(1): 2172671. doi:10.1080/19490976.2023.2172671.
30. Dikeocha IJ, Al-Kabsi AM, Miftahussurur M, Alshawsh MA. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism. The FASEB Journal. 2022 May 17;36(6): e22468. doi:10.1096/fj.202201376RR.
31. Dikeocha IJ, Al-Kabsi AM, Miftahussurur M, Alshawsh MA. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism. The FASEB Journal. 2022 May 17; 36(6): e22468. doi:10.1096/fj.202201376RR.
32. Wan Y, Zuo T. Interplays between drugs and the gut microbiome. Gastroenterology Report. 2022 Apr 8; 10: goac009. doi:10.1093/gastro/goac009.
33. Pandey H, Jain D, Tang DWT, Wong SH, Lal D. Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease. Intest Res. 2024 Jan; 22(1): 15–43. doi:10.5217/ir.2023.00080.
34. Chae WR. Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma. Journal of Translational Medicine. 2023 Mar 16; 21(1): 198. doi:10.1186/s12967-023-04042-5.
35. Liu B, Zhang L, Yang H, Zheng H, Liao X. Microbiota: A potential orchestrator of antidiabetic therapy. Frontiers in Endocrinology. 2023 Jan 27; 14: 109810. doi:10.3389/fendo.2023.109810.
36. Nishida A, Nishino K, Ohno M, Sakai K, Owaki Y, Noda Y, et al. Update on gut microbiota in gastrointestinal diseases. World Journal of Clinical Cases. 2022 Aug 6; 10(22): 7653–64. doi:10.12998/wjcc. v10.i22.7653.
37. Liu W, Luo Z, Zhou J, Sun B. Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus. Frontiers in Cellular and Infection Microbiology. 2022 May 31; 12: 931056. doi:10.3389/fcimb.2022.931056.
38. Del Chierico F, Rapini N, Deodati A, Matteoli MC, Cianfarani S, Putignani L. Pathophysiology of Type 1 Diabetes and Gut Microbiota Role. IJMS. 2022 Nov 24; 23(23): 14650. doi:10.3390/ijms232314650.
39. Liu W, Luo Z, Zhou J, Sun B. Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus. Frontiers in Cellular and Infection Microbiology. 2022 May 31; 12: 931056. doi:10.3389/fcimb.2022.931056.
40. Munshi R, Solanki S, Karande AA, Ranganathan P. Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration. Frontiers in Neurology. 2023 May 15; 14: 1149618. doi:10.3389/fneur.2023.1149618.
41. Kim D-H. Gut Microbiota-Mediated Drug-Antibiotic Interactions. Drug Metabolism and Disposition. 2015 Oct 1; 43(10): 1581–9. doi: 10.1124/dmd.115.063867.
42. Westberg J, Keranda Kabupaten Bima J. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. Journal of Hematology & Oncology. 2022 Apr 29; 15(1). doi: 10.1186/s13045-022-01273-9.
43. Swanson HI. Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry? Drug Metabolism and Disposition. 2015 Oct 1; 43(10): 1499–504. doi: 10.1124/dmd.115.063867.
44. Belvoncikova P, Maronek M, Gardlik R. Gut Dysbiosis and Fecal Microbiota Transplantation in Autoimmune Diseases. International Journal of Molecular Sciences. 2022 Sep 14; 23(18): 10729. doi: 10.3390/ijms231810729.
45. Skok P, Skok K. Gut microbiota and the pathophysiology of cardiovascular disease. Archives of Medical Science. 2021. doi: 10.5114/aoms/127177
46. Chen J. The role of gut microbiota in digestive system cancers: mechanisms and potential therapeutic targets. Theoretical and Natural Science. 2024 Dec 12; 70(1): 62–7. doi: 10.54254/2753-8818/2024.18231.
47. Fan D, Hu J, Lin N. Effects of probiotics, prebiotics, synbiotics and postbiotics on pediatric asthma: a systematic review. Frontiers in Nutrition. 2025 Apr 25; 12. doi: 10.3389/fnut.2025.1586129.
48. Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020 Aug; 69(8): 1510–9. doi: 10.1136/gutjnl-2019-320204.
49. Hamamah S, Gheorghita R, Lobiuc A, Sirbu IO, Covasa M. Fecal microbiota transplantation in non-communicable diseases: Recent advances and protocols. Frontiers in Medicine. 2022. doi: 10.3389/fmed.2022.1023456.
50. Chou S, Zhang S, Guo H, Chang Y-F, Zhao W, Mou X. Targeted Antimicrobial Agents as Potential Tools for Modulating the Gut Microbiome. Frontiers in Microbiology. 2022 Jul 7. doi: 10.3389/fmicb.2022.877129.
51. Siraj S. Role of Microbiome in Personalized Medicine. Precision Medicine Communications. 2023 Dec 31; 3(2): 79. doi: 10.1186/s44156-023-00013-3.
52. Lam KN, Alexander M, Turnbaugh PJ. Precision Medicine Goes Microscopic: Engineering the Microbiome to Improve Drug Outcomes. Cell Host & Microbe. 2019 Jul; 26(1): 22–34. DOI: 10.1016/j.chom.2019.06.004.
53. Liu Z, de Vries B, Gerritsen J, Smidt H, Zoetendal EG. Microbiome-based stratification to guide dietary interventions to improve human health. Nutrition Research. 2020 Oct; 82: 1–10. DOI: 10.1016/j.nutres.2020.06.002.
54. Gulliver EL, Young RB, Chonwerawong M, D’Adamo GL, Thomason T, Widdop JT, et al. Review article: the future of microbiome-based therapeutics. Aliment Pharmacol Ther. 2022 Jul; 56(2): 192–208. DOI: 10.1111/apt.17049.
55. Lee HL, Shen H, Hwang IY, Ling H, Yew WS, Lee YS, et al. Targeted Approaches for In Situ Gut Microbiome Manipulation. Genes. 2018 Jul 12; 9(7):351. DOI: 10.3390/genes9070351.
56. Lanthier N, Delzenne NM. Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time? Cells. 2022 Aug 31; 11(17): 2718. DOI: 10.3390/cells11172718.
57. Cryan JF, de Wit H. The gut microbiome in psychopharmacology and psychiatry. Psychopharmacology (Berl). 2019 May; 236(5): 1407–9. DOI: 10.1007/s00213-019-05288-y.
58. Ejtahed H-S, Soroush A, Angoorani P, Larijani B, Hasani-Ranjbar S. Gut Microbiota as a Target in the Pathogenesis of Metabolic Disorders: A New Approach to Novel Therapeutic Agents. Hormone and Metabolic Research. 2016 May 20; 48(6): 349–58. DOI: 10.1055/s-0042-107792.
59. Vich Vila A, Collij V, Sanna S, Sinha T, Imhann F, Bourgonje AR, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature Communications. 2020 Jan 17; 11(1): 362. DOI: 10.1038/s41467-019-14177-z.
60. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacology & Therapeutics. 2011; 130(2): 202–12. DOI: 10.1016/j.pharmthera.2011.01.008.
61. Sumit SD. Targeting the Microbiome: New Frontiers in Drug Development and Therapeutic Strategies. Scholar’s Digest: Journal of Pharmacology. 2025; 1(1): 56–75. Available at: https://scholarsdigest.org.in/index.php/sdjph/article/view/93
62. Feng W, Liu J, Ao H, Yue S, Peng C. Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs. Theranostics. 2020; 10(24): 11278–11301. https://doi.org/10.7150/thno.47289.
63. Zhu LR, Li SS, Zheng WQ, Ni WJ, Cai M, Liu HP. Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy. Front Immunol. 2023; 14:1086078. https://doi.org/10.3389/fimmu.2023.1086078.
64. Izzo AA. Novel insights which may translate into treatments for irritable bowel syndrome. Front Pharmacol [Internet]. 2013 Dec 31; 4: 160. Available from: https://doi.org/10.3389/fphar.2013.00160.
65. Izzo AA, Capasso R, Aviello G, et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol. 2012 Jun; 166(4): 1444–60. Available from: https://doi.org/10.1111/j.1476-5381.2012.01879.x
66. Angelo A. Izzo, Izzo AA, Raffaele Capasso, Capasso R, Gabriella Aviello, Aviello G, et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. British Journal of Pharmacology. 2012 Jun 1; 166(4): 1444–60. doi: 10.1111/j.1476-5381.2012. 01879.x
67. Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol [Internet]. 2019 Mar 4 [cited 2025 Jul 17];13(3):193–204.
68. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov [Internet]. 2008 Feb; 7(2): 123–9.
69. Zhu M, Liu X, Ye Y, Yan X, Cheng Y, Zhao L, et al. Gut microbiota: a novel therapeutic target for Parkinson’s disease. Front Immunol [Internet]. 2022 [cited 2025 Jul 17]; 13:937555.
70. Belizário JE, Faintuch J, Garay-Malpartida M. Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases. Mediators Inflamm [Internet]. 2018 Dec 9; 2018:2037838.
71. Zhao Q, Chen Y, Huang W, Zhou H, Zhang W. Drug-microbiota interactions: an emerging priority for precision medicine. Signal Transduction and Targeted Therapy. 2023; 8(1): 386. https://doi.org/10.1038/s41392-023-01597-2
72. Izzo AA, Coutts AA. Cannabinoids and the digestive tract. In: Handbook of Experimental Pharmacology. 2005; 168: 573–98. https://doi.org/10.1007/3-540-26573-2_21
73. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacology & Therapeutics. 2011; 130(2): 202–12. https://doi.org/10.1016/j.pharmthera.2011.01.012
74. Sumit SD. Targeting the Microbiome: New Frontiers in Drug Development and Therapeutic Strategies. Scholar’s Digest: Journal of Pharmacology. 2025; 1(1): 56–75. https://scholarsdigest.org.in/index.php/sdjph/article/view/93
75. Feng W, Liu J, Ao H, Yue S, Peng C. Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs. Theranostics. 2020; 10(24): 11278–11301. https://doi.org/10.7150/thno.47289
76. Zhu LR, Li SS, Zheng WQ, Ni WJ, Cai M, Liu HP. Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy. Front Immunol. 2023;14:1086078. https://doi.org/10.3389/fimmu.2023.1086078
77. Izzo AA. Novel insights which may translate into treatments for irritable bowel syndrome. Front Pharmacol. 2013; 4: 160. https://doi.org/10.3389/fphar.2013.00160
78. Izzo AA, Capasso R, Aviello G, et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol. 2012; 166(4): 1444–60. https://doi.org/10.1111/j.1476-5381.2012.01879.x
79. Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019; 13(3): 193–204. https://doi.org/10.1080/17474124.2019.1575244
80. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008;7(2):123–9. https://doi.org/10.1038/nrd2462
81. Zhu M, Liu X, Ye Y, Yan X, Cheng Y, Zhao L, et al. Gut microbiota: a novel therapeutic target for Parkinson’s disease. Front Immunol. 2022; 13: 937555. https://doi.org/10.3389/fimmu.2022.937555.
82. Izzo AA, Coutts AA. Cannabinoids and the digestive tract. Handb Exp Pharmacol. 2005; (168): 573–98. doi: 10.1007/3-540-26573-2_19.
83. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008 Feb;7(2):123–9. doi: 10.1038/nrd2505.
84. Karakan T. Gut microbiota modulation in cirrhosis: A new frontier in hepatology. Turk J Gastroenterol. 2014 May 21; 25(1): 126. doi: 10.5152/tjg.2014.0007.
85. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008; 7(2): 123–9. https://doi.org/10.1038/nrd2462
86. Karakan T. Gut microbiota modulation in cirrhosis: A new frontier in hepatology. Turk J Gastroenterol. 2014; 25(1): 126. doi: 10.5152/tjg.2014.0007.
87. Wu J, Singleton SS, Bhuiyan U, Krammer L, Mazumder R. Multi-omics approaches to studying gastrointestinal microbiome in the context of precision medicine and machine learning. Front Mol Biosci. 2024 Jan 19;10: 10.3389/fmolb.2023.1337373.
88. Chetty A, Blekhman R. Multi-omic approaches for host-microbiome data integration. Gut Microbes. 2024 Dec 31; 16(1): 10.1080/19490976.2023.2297860.
89. Logotheti M, Agioutantis P, Katsaounou P, Loutrari H. Microbiome Research and Multi-Omics Integration for Personalized Medicine in Asthma. J Pers Med. 2021 Dec 5; 11(12): 1299. doi: 10.3390/jpm11121299.
90. Zhang Y, Thomas JP, Korcsmaros T, Gul L. Integrating multi-omics to unravel host-microbiome interactions in inflammatory bowel disease. Cell Rep Med. 2024 Sep 17; 5(9): 101738. doi: 10.1016/j.xcrm.2024.101738.
91. Duan D, Wang M, Han J, Li M, Wang Z, Zhou S, et al. Advances in multi-omics integrated analysis methods based on the gut microbiome and their applications. Front Microbiol. 2025 Jan 3; 10.3389/fmicb.2024.1509117.
92. Kaur H, Kaur A, Singh M. Gut Microbiota in Drug Metabolism: A New Frontier in Precision Medicine. Int J Sci Res Eng Manag. 2025 May 8; 9(5): 1–9. doi: 10.55041/IJSREM47264.